The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

ESMO WCGIC 2020 | Impact of p-mTOR expression on molecular-guided therapy in PDAC

Name: Impact of p-mTOR expression on molecular-guided therapy in PDAC
Uploaded: 2020-06-23T00:00:00Z
Duration: 1 min 32 s
Description: Hossein Taghizadeh, MD, Medical University of Vienna, Vienna, Austria, outlines the significance of phosphorylated mTOR (p-mTOR) expression on molecular guided therapy strategies in refractory metastatic pancreatic ductal adenocarcinoma (PDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Hossein Taghizadeh • 23 Jun 2020

ESMO WCGIC 2020

Gastrointestinal Cancer Pancreatic Cancer Everolimus

Hossein Taghizadeh, MD, Medical University of Vienna, Vienna, Austria, outlines the significance of phosphorylated mTOR (p-mTOR) expression on molecular guided therapy strategies in refractory metastatic pancreatic ductal adenocarcinoma (PDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).